br Biering S rensen T Biering S rensen
29. Biering-Sørensen T, Biering-Sørensen SR, Olsen FJ, et al. Global longitudinal strain by echocardiography predicts long-term risk of cardiovascular morbidity and mortality in a low-risk general popula-tion: The Copenhagen City Heart Study. Circ Cardiovasc Imaging 2017;10:e005521.
30. Russo C, Jin Z, Elkind MSV, et al. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort HHS public access. Eur J Heart Fail 2014;16:1301-1309.
31. Cheng S, McCabe EL, Larson MG, et al. Distinct aspects of left ventricular mechanical function are differentially associated with
400 van den Bogaard et al. International Journal of Radiation Oncology Biology Physics
cardiovascular outcomes and all-cause mortality in the community. J Am Heart Assoc 2015;4:e002071.
33. Correa CR, Litt HI, Hwang WT, et al. Coronary artery find-ings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25: 3031-3037.
36. Saiki H, Petersen IA, Scott CG, et al. Risk of 1018675-35-8 failure with pre-served ejection fraction in older women after contemporary radio-therapy for breast cancer. Circulation 2017;135:1388-1396.
37. Gyenes G, Fornander T, Carlens P, et al. Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy.
Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer
Katelyn M. Atkins, MD, PHD,a Bhupendra Rawal, MS,b Tafadzwa L. Chaunzwa, BS,c,d Nayan Lamba, BA,e Danielle S. Bitterman, MD,a Christopher L. Williams, PHD,d David E. Kozono, MD, PHD,d r> ABSTRACT
BACKGROUND Radiotherapy-associated cardiac toxicity studies in patients with locally advanced non–small cell lung cancer (NSCLC) have been limited by small sample size and nonvalidated cardiac endpoints.
OBJECTIVES The purpose of this analysis was to ascertain whether cardiac radiation dose is a predictor of major adverse cardiac events (MACE) and all-cause mortality (ACM).
METHODS This retrospective analysis included 748 consecutive locally advanced NSCLC patients treated with thoracic radiotherapy. Fine and Gray and Cox regressions were used to identify predictors for MACE and ACM, adjusting for lung cancer and cardiovascular prognostic factors, including pre-existing coronary heart disease (CHD).
CONCLUSIONS Despite the competing risk of cancer-specific death in locally advanced NSCLC patients, cardiac radiation dose exposure is a modifiable cardiac risk factor for MACE and ACM, supporting the need for early recognition and treatment of cardiovascular events and more stringent avoidance of high cardiac radiotherapy dose. (J Am Coll Cardiol 2019;73:2976–87) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Listen to this manuscript’s audio summary by Editor-in-Chief
Dr. Valentin Fuster on JACC.org.
From the aHarvard Radiation Oncology Program, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts; bDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; cYale School of Medicine, New Haven, Connecticut; dDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts; eHarvard Medical School, Boston, Massachusetts; fDepartment of Cardiovascular Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachu-setts; gDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and the hDepartment of Radiology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts. Dr. Williams has received research grants from Varian Medical Systems. Dr. Nguyen has received consulting fees from Blue Earth, Ferring, Janssen, Astellas, Cota, Nanobiotix, Genome DX, Augmenix, Boston Scientific, Dendreon, and Bayer; and has received grants (to institution) from Janssen and Astellas. Dr. Nohria has received a research grant (to institution) from Amgen; and has served as a consultant for Takeda Oncology. Dr. Hoffmann has received research grants (to institution) from Medimmune, Kowa, and HeartFlow Inc. Dr. Aerts has received consulting fees from Sphera and Genospace. Dr. Mak has served on the Scientific Advisory Board of AstraZeneca; and has received an honorarium from NewRT. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.